Eli Lilly and Co (LSE:LEL) Beginning Cash Position : $2,819 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Eli Lilly and Co Beginning Cash Position?

Eli Lilly and Co's Beginning Cash Position for the quarter that ended in Mar. 2024 was $2,819 Mil.

Eli Lilly and Co's quarterly Beginning Cash Position declined from Sep. 2023 ($2,695 Mil) to Dec. 2023 ($2,381 Mil) but then increased from Dec. 2023 ($2,381 Mil) to Mar. 2024 ($2,819 Mil).

Eli Lilly and Co's annual Beginning Cash Position increased from Dec. 2021 ($3,657 Mil) to Dec. 2022 ($3,819 Mil) but then declined from Dec. 2022 ($3,819 Mil) to Dec. 2023 ($2,067 Mil).

Eli Lilly and Co Beginning Cash Position Historical Data

The historical data trend for Eli Lilly and Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Beginning Cash Position Chart

Eli Lilly and Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

7,998.20

2,337.50

3,657.10

3,818.50

2,067.00

Eli Lilly and Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															2,067.00	3,545.90	2,694.50	2,380.80	2,818.60

Eli Lilly and Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Eli Lilly and Co Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Eli Lilly and Co (LSE:LEL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (LSE:LEL) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

LLY:USA LLY:Mexico 1LLY:Italy LLY:Germany LLY:Switzerland LLY:Canada LILY34:Brazil LLYC:Austria LLY:Argentina

Address

Lilly Corporate Center, Indianapolis, IN, USA, 46285

Website

https://www.lilly.com

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Co (LSE:LEL) Headlines

No Headlines